{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:14:06Z","timestamp":1793830446318,"version":"4.6.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"national institutes of health","doi-asserted-by":"publisher","award":["P30CA014520"],"award-info":[{"award-number":["P30CA014520"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00259-021-05563-1","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T11:02:37Z","timestamp":1631617357000},"page":"861-870","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["ImmunoPET of trophoblast cell-surface antigen 2 (Trop-2) expression in pancreatic cancer"],"prefix":"10.1007","volume":"49","author":[{"given":"Weiyu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhsin H.","family":"Younis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd E.","family":"Barnhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuanwei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Engle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4641-0833","authenticated-orcid":false,"given":"Weibo","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,14]]},"reference":[{"key":"5563_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"5563_CR2","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0140-6736(10)62307-0","volume":"378","author":"A Vincent","year":"2011","unstructured":"Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607\u201320.","journal-title":"Lancet"},{"key":"5563_CR3","doi-asserted-by":"publisher","first-page":"1901724","DOI":"10.1002\/advs.201901724","volume":"6","author":"W Chen","year":"2019","unstructured":"Chen W, Ni D, Rosenkrans ZT, Cao T, Cai W. Smart H2S-triggered\/therapeutic system (SHTS)-based nanomedicine. Adv Sci. 2019;6:1901724.","journal-title":"Adv Sci"},{"key":"5563_CR4","doi-asserted-by":"publisher","first-page":"1904833","DOI":"10.1002\/adfm.201904833","volume":"29","author":"T Sun","year":"2019","unstructured":"Sun T, Jiang D, Rosenkrans ZT, Ehlerding EB, Ni D, Qi C, et al. A melanin-based natural antioxidant defense nanosystem for theranostic application in acute kidney injury. Adv Funct Mater. 2019;29:1904833.","journal-title":"Adv Funct Mater"},{"key":"5563_CR5","first-page":"107","volume":"11","author":"YXJ Wang","year":"2021","unstructured":"Wang YXJ, Huang H, Zheng CJ, Xiao BH, Chevallier O, Wang W. Diffusion-weighted MRI of the liver: challenges and some solutions for the quantification of apparent diffusion coefficient and intravoxel incoherent motion. Am J Nucl Med Mol Imaging. 2021;11:107\u201342.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"5563_CR6","first-page":"2037","volume":"9","author":"M Li","year":"2019","unstructured":"Li M, Jiang D, Barnhart TE, Cao T, Engle JW, Chen W, et al. Immuno-PET imaging of VEGFR-2 expression in prostate cancer with (89)Zr-labeled ramucirumab. Am J Cancer Res. 2019;9:2037\u201346.","journal-title":"Am J Cancer Res"},{"key":"5563_CR7","doi-asserted-by":"publisher","first-page":"1902956","DOI":"10.1002\/adma.201902956","volume":"31","author":"D Ni","year":"2019","unstructured":"Ni D, Wei H, Chen W, Bao Q, Rosenkrans ZT, Barnhart TE, et al. Ceria nanoparticles meet hepatic ischemia-reperfusion injury: the perfect imperfection. Adv Mater. 2019;31:1902956.","journal-title":"Adv Mater"},{"key":"5563_CR8","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s12274-019-2271-5","volume":"12","author":"D Jiang","year":"2019","unstructured":"Jiang D, Im H-J, Boleyn ME, England CG, Ni D, Kang L, et al. Efficient renal clearance of DNA tetrahedron nanoparticles enables quantitative evaluation of kidney function. Nano Res. 2019;12:637\u201342.","journal-title":"Nano Res"},{"key":"5563_CR9","first-page":"279","volume":"10","author":"PB Gelezhe","year":"2020","unstructured":"Gelezhe PB, Blokhin IA, Marapov DI, Morozov SP. Quantitative parameters of MRI and (18)F-FDG PET\/CT in the prediction of breast cancer prognosis and molecular type: an original study. Am J Nucl Med Mol Imaging. 2020;10:279\u201392.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"5563_CR10","first-page":"334","volume":"10","author":"DM Paul","year":"2020","unstructured":"Paul DM, Ghiuzeli CM, Rini J, Palestro CJ, Fung EK, Ghali M, et al. A pilot study treatment of malignant tumors using low-dose 18F-fluorodeoxyglucose (18F-FDG). Am J Nucl Med Mol Imaging. 2020;10:334.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"5563_CR11","first-page":"99","volume":"11","author":"F Kaghazchi","year":"2021","unstructured":"Kaghazchi F, Borja AJ, Hancin EC, Bhattaru A, Detchou DKE, Seraj SM, et al. Venous thromboembolism detected by FDG-PET\/CT in cancer patients: a common, yet life-threatening observation. Am J Nucl Med Mol Imaging. 2021;11:99\u2013106.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"5563_CR12","first-page":"1249","volume":"28","author":"T Belhocine","year":"2006","unstructured":"Belhocine T, Spaepen K, Dusart M, Castaigne C, Muylle K, Bourgeois P, et al. 18FDG PET in oncology: the best and the worst (Review). Int J Oncol. 2006;28:1249\u201361.","journal-title":"Int J Oncol"},{"key":"5563_CR13","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1007\/s00259-017-3663-y","volume":"44","author":"D Jiang","year":"2017","unstructured":"Jiang D, Im H-J, Sun H, Valdovinos HF, England CG, Ehlerding EB, et al. Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer. Eur J Nucl Med Mol Imaging. 2017;44:1296\u2013305.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5563_CR14","doi-asserted-by":"publisher","first-page":"28989","DOI":"10.18632\/oncotarget.25615","volume":"9","author":"DM Goldenberg","year":"2018","unstructured":"Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018;9:28989.","journal-title":"Oncotarget"},{"key":"5563_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/(SICI)1097-0215(19980529)76:5<671::AID-IJC10>3.0.CO;2-7","volume":"76","author":"E Rapani","year":"1998","unstructured":"Rapani E, Sacchetti A, Corda D, Alberti S. Human Trop-2 is a tumor-associated calcium signal transducer. Int J Cancer. 1998;76:671\u20136.","journal-title":"Int J Cancer"},{"key":"5563_CR16","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/onc.2012.36","volume":"32","author":"M Trerotola","year":"2013","unstructured":"Trerotola M, Cantanelli P, Guerra E, Tripaldi R, Aloisi A, Bonasera V, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene. 2013;32:222\u201333.","journal-title":"Oncogene"},{"key":"5563_CR17","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.ejca.2009.12.019","volume":"46","author":"E Bignotti","year":"2010","unstructured":"Bignotti E, Todeschini P, Calza S, Falchetti M, Ravanini M, Tassi RA, et al. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur J Cancer. 2010;46:944\u201353.","journal-title":"Eur J Cancer"},{"key":"5563_CR18","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/sj.bjc.6604677","volume":"99","author":"D Fong","year":"2008","unstructured":"Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, Mitterer M, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer. 2008;99:1290\u20135.","journal-title":"Br J Cancer"},{"key":"5563_CR19","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","volume":"380","author":"A Bardia","year":"2019","unstructured":"Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380:741\u201351.","journal-title":"N Engl J Med"},{"key":"5563_CR20","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s00259-013-2434-7","volume":"40","author":"CM van Rij","year":"2013","unstructured":"van Rij CM, L\u00fctje S, Frielink C, Sharkey RM, Goldenberg DM, Franssen GM, et al. Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody. Eur J Nucl Med Mol Imaging. 2013;40:1377\u201383.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5563_CR21","doi-asserted-by":"publisher","first-page":"6216","DOI":"10.1158\/0008-5472.CAN-14-0594","volume":"74","author":"S L\u00fctje","year":"2014","unstructured":"L\u00fctje S, Rijpkema M, Goldenberg DM, van Rij CM, Sharkey RM, McBride WJ, et al. Pretargeted dual-modality immuno-SPECT and near-infrared fluorescence imaging for image-guided surgery of prostate cancer. Cancer Res. 2014;74:6216\u201323.","journal-title":"Cancer Res"},{"key":"5563_CR22","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.2147\/OTT.S162447","volume":"12","author":"S Zaman","year":"2019","unstructured":"Zaman S, Jadid H, Denson AC, Gray JE. Targeting Trop-2 in solid tumors: future prospects. OncoTargets Ther. 2019;12:1781.","journal-title":"OncoTargets Ther"},{"key":"5563_CR23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11307-014-0772-x","volume":"17","author":"CM van Rij","year":"2015","unstructured":"van Rij CM, Frielink C, Goldenberg DM, Sharkey RM, Franssen GM, L\u00fctje S, et al. Pretargeted immunoPET of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody in mice with PC3 xenografts. Mol Imaging Biol. 2015;17:94\u2013101.","journal-title":"Mol Imaging Biol"},{"key":"5563_CR24","first-page":"323","volume":"29","author":"CM van Rij","year":"2014","unstructured":"van Rij CM, Frielink C, Goldenberg DM, Sharkey RM, L\u00fctje S, McBride WJ, et al. Pretargeted radioimmunotherapy of prostate cancer with an anti-TROP-2\u00d7 Anti-HSG bispecific antibody and a 177Lu-Labeled Peptide. Cancer Biother. 2014;29:323\u20139.","journal-title":"Cancer Biother"},{"key":"5563_CR25","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/sj.bjc.6604677","volume":"99","author":"D Fong","year":"2008","unstructured":"Fong D, Moser P, Krammel C, Gostner J, Margreiter R, Mitterer M, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer. 2008;99:1290.","journal-title":"Br J Cancer"},{"key":"5563_CR26","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.2967\/jnumed.112.105460","volume":"53","author":"H Hong","year":"2012","unstructured":"Hong H, Zhang Y, Nayak TR, Engle JW, Wong HC, Liu B, et al. Immuno-PET of tissue factor in pancreatic cancer. J Nucl Med. 2012;53:1748\u201354.","journal-title":"J Nucl Med"},{"key":"5563_CR27","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1021\/acs.molpharmaceut.6b00132","volume":"13","author":"CG England","year":"2016","unstructured":"England CG, Kamkaew A, Im H-J, Valdovinos HF, Sun H, Hernandez R, et al. ImmunoPET imaging of insulin-like growth factor 1 receptor in a subcutaneous mouse model of pancreatic cancer. Mol Pharm. 2016;13:1958\u201366.","journal-title":"Mol Pharm"},{"key":"5563_CR28","doi-asserted-by":"crossref","unstructured":"Rosenkrans ZT, Cai W. Total-body PET imaging for up to 30 days after injection of 89Zr-labeled antibodies. J Nucl Med. 2020;61:451\u20132.","DOI":"10.2967\/jnumed.119.236166"},{"key":"5563_CR29","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1097\/mpa.0b013e31814de421","volume":"36","author":"B Agarwal","year":"2008","unstructured":"Agarwal B, Correa AM, Ho L. Survival in pancreatic carcinoma based on tumor size. Pancreas. 2008;36:e15\u201320.","journal-title":"Pancreas"},{"key":"5563_CR30","first-page":"168","volume":"2","author":"P Tummala","year":"2011","unstructured":"Tummala P, Junaidi O, Agarwal B. Imaging of pancreatic cancer: an overview. J Gastrointest. 2011;2:168.","journal-title":"J Gastrointest"},{"key":"5563_CR31","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.4103\/2230-8210.83060","volume":"15","author":"V Chaudhary","year":"2011","unstructured":"Chaudhary V, Bano S. Imaging of the pancreas: recent advances. Indian J Endocrinol Metab. 2011;15:S25.","journal-title":"Indian J Endocrinol Metab"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05563-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-021-05563-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05563-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T12:07:49Z","timestamp":1643630869000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-021-05563-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,14]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["5563"],"URL":"https:\/\/doi.org\/10.1007\/s00259-021-05563-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,14]]},"assertion":[{"value":"6 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The current study does not include any studies associated with human participants. And this work follows all applicable guidelines (international, national, and\/or institutional) for the care and use of animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Weibo Cai is a scientific advisor, stockholder, and grantee of Focus-X Therapeutics, Inc. All other authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}